Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Chronic Constipation

Faming Zhang

Status: Not yet enrolling

Conditions: Chronic Constipation

Treatments: Drug: Placebo; Drug: Ornidazole

Study type: Interventional

Funder types: Other

Identifiers

NCT06427863

WMT-Anti-CC-202405

Details and patient eligibility

About

This is a randomized controlled trial to explore the efficacy of antibiotic pretreatment on the efficacy of WMT in the treatment of chronic constipation in adults: a multi-center, randomized, placebo-controlled clinical study

Full description

All included in the standard but do not accord with standard of any rule out subjects will be included in this study. Demographic characteristics, complete spontaneous bowel movements（CSBM), Constipation assessment scale (CAS), Patient-Assessment of Constipation Quality Of Life（PAC-QOL) and clinical outcomes were collected. After the treatment, the efficacy and safety were evaluated during the follow-up period.

Enrollment: 96 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Subjects must meet all of the following inclusion criteria to enter the study:

1. Male and female, aged ≥18 years old, provided written informed consent;
2. Subjects diagnosed with chronic constipation, with a duration of at least 6 months, and with the following conditions:

1. spontaneous bowel movement frequency <3 times/week (spontaneous bowel movement was defined as spontaneous bowel movement without rescue laxatives or manual assistance); 2) waste hard: at least 25% of defecation in Bristol stool traits scale type 1 or 2.

3. The subjects or their legal representatives gave informed consent, fully understood the purpose of the study, were able to communicate well with the researchers, and understood and complied with the requirements of the study.

Exclusion criteria

Subjects meeting any of the following exclusion criteria must be excluded fromthe study:

1. Presence of outlet obstruction and constipation, such as rectal mucosal prolapse

2. Combined with the results of colonoscopy in the past 24 months, those with intestinal stenosis caused by organic lesions of the digestive tract (such as tumor, inflammation, anal fissure, Crohn's disease, ulcerative colitis, intestinal adhesion, intestinal tuberculosis, etc.) and constipation;

3. Constipation caused by other systemic diseases involving the digestive tract, such as nervous system diseases (such as Parkinson's disease, spinal cord injury, multiple sclerosis, etc.), muscle diseases (such as amyloidosis, dermatomyositis, etc.), mental disorders (such as depression, etc.), metabolic and endocrine disorders (such as diabetes, hypothyroidism, etc.) or opioids, etc.

4. Has a history of abdominal pelvic surgery, but after cystic resection, cesarean section, does not appear after appendectomy postoperative intestinal complications, and intestinal polyps except after treatment;

5. Has a history of major surgery within 3 months or a history of severe trauma, and recovery is not completely;

6. There are contraindications to colonic transendoscopic intestinal tube implantation, such as severe intestinal stenosis, obstruction, deep ulcer, and high risk of operation perforation; Severe ulcers or a large number of pseudopolyps exist in the fixed area of titanium clips, which are not suitable for fixation. The subjects' behavior was seriously uncontrolled.

7. Any of the following abnormalities in cardiac function and performance:

   1. According to the New York Heart Association (NYHA) cardiac function classification, cardiac function grade Ⅲ or above;
   2. new onset myocardial infarction or unstable angina pectoris within 6 months;
   3. ECG showed QTc prolongation (QTc≥ 450ms in men and ≥470ms in women);
   4. Drug-refractory atrial arrhythmias and drug-refractory ventricular arrhythmias (including grade 2 or higher atrioventricular block).

8. Patients with poor lung function that is considered by the investigator to have an impact on the study treatment, such as patients with acute exacerbation of COPD or patients requiring long-term use of oral or intravenous steroids for control (except inhalers/sprays);

9. No control autoimmune disease and/or need long-term use of hormone (except local external use sex);

10. Patients with metabolic diseases and poorly controlled by drugs (such as thyroid dysfunction), or patients with metabolic diseases accompanied by gastrointestinal function complications (such as gastrointestinal autonomic nerve dysfunction, diabetic gastroparesis, etc.);

11. Suffering from reproductive system diseases (including but not limited to ovarian cysts, endometriosis, primary dysmenorrhea, etc.) that may lead to abdominal pain;

12. Significant laboratory abnormalities that, in the judgment of the investigator, may affect the safety of the subjects or the completion of the clinical study, including:

    A) the hemoglobin < 100 g/L; B) Serum creatinine ≥1.5 times the upper limit of normal (ULN) C) abnormal liver function, defined as AST>1.5×ULN and/or ALT>1.5×ULN and/or total bilirubin >1.5×ULN; D) blood clotting function: PLT acuities were 80 x 109 / L, APTT > 1.5 x ULN, PT > 1.5 x ULN, INR > 1.5 x ULN; E) abnormal results or defecate occult blood stool and has prompted the clinical significance of the gastrointestinal tract.

13. Have active hepatitis (requiring or taking long-term treatment), HIV, or active tuberculosis;

14. A history of drug or alcohol abuse (i.e., drinking more than 14 servings per week of beer, 45 mL of 40% spirits, or 150 mL of wine) or substance abuse;

15. The known allergic to research similar drugs, drugs or accessories;

16. Use of anti-infective drugs (antibiotics, antifungal, antiviral) within 14 days before enrollment, or need anti-infective treatment at enrollment evaluation;

17. Drugs and supplements that affect gastrointestinal motility and function cannot be stopped during the study, including but not limited to: antibiotics such as erythromycin; Drugs that modulate the intestinal microecology, such as probiotics such as Bifidobacterium; The parasympathetic nerve inhibitors, some scopolamine and atropine, belladonna, etc; Muscle relaxants, such as succinylcholine; Antidiarrheal agents such as loperamide, smecta; Opioid preparations; Drugs that inhibit gastric acid secretion;

18. Pregnant or lactating women, or refusing to use an effective contraceptive method within 3 months after the last dose of treatment;

19. 3 months prior to dosing involved in drug interventional clinical trials;

20. Suffering from malignant tumors;

21. There were other circumstances that the investigator considered inappropriate for participating in the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

96 participants in 2 patient groups, including a placebo group

Treatment

Experimental group

Description:

Patients will receive three enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT once daily for a duration of 3 days.

Treatment:

Drug: Ornidazole

Control

Placebo Comparator group

Description:

Patients will receive three enemas of a placebo of equal volume through the TET tube, followed by WMT once daily for a duration of 3 days.

Treatment:

Drug: Placebo